Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A.
- Do you, or did you, own shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ CM: CPRX )?
- Did you purchase your shares before October 31, 2012, or between October 31, 2012 and October 18, 2013, inclusive?
- Did you lose money in your investment in Catalyst Pharmaceutical Partners, Inc.?
- Do you want to discuss your rights?
, including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the Southern District of Florida on behalf of all persons or entities that purchased the common stock of Catalyst Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”) (NASDAQ CM:
) between October 31, 2012 and October 18, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Catalyst during the Class Period, or purchased shares prior to the Class Period and still hold Catalyst, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact
Timothy J. MacFall, Esquire
or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to
, or at:
Catalyst is a development-stage specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting (rare) orphan neuromuscular and neurological diseases and disorders. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that one of Catalyst’s competitors – a private pharmaceutical company called Jacobus Pharmaceuticals (“Jacobus”) – had been manufacturing a drug biologically equivalent to one of Catalyst’s developmental products, Firdapse, and had been providing it to patients free of charge for decades. As a result of defendants’ false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.